Key facts
- This page summarizes David Tapolczay's Form 4 filing for CONDUIT PHARMACEUTICALS INC. (CDT).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 Apr 2024, 17:00.
David Tapolczay - 22 Apr 2024 Form 4 Insider Report for CONDUIT PHARMACEUTICALS INC. (CDT)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- CDT
- Reported as of
- 22 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Apr 2024, 17:00:26 UTC
- Prior SEC filing
- 05 Dec 2023
- Next SEC filing
- 20 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Tapolczay
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Tapolczay filed Form 4 for CONDUIT PHARMACEUTICALS INC. (CDT) on 24 Apr 2024.
Change
- Previous filing in this sequence was filed on 05 Dec 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CDT
transaction
Derivative
Warrant (Right to buy)
Award
- Transaction value
- Shares
- +400,664
- Change %
- Price
- Shares after
- 400,664
- Date
- 22 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 400,664
- Exercise price
- $3.12
- Footnotes
- F1
CDT
transaction
Derivative
Warrant (Right to buy)
Sale
- Transaction value
- Shares
- -200,332
- Change %
- -50%
- Price
- Shares after
- 200,332
- Date
- 22 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,332
- Exercise price
- $3.12
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Warrants issued in exchange for one year lock-up of reporting person's common stock of the company, par value $0.0001 per share, and the payment of $0.125 per warrant.
Footnote F2
Warrants sold in exchange for $0.25 per warrant in private transaction.